Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2020; 41(03): 358-367
DOI: 10.4103/ijmpo.ijmpo_196_18
Original Article

Epidemiologic Study of Patients Registered in Oncology Unit at a Hepatobiliary Tertiary Care Center in India

Namita Sharma
Department of Medical Oncology, Institute of Liver and Biliary Sciences, Delhi, India
,
Guresh Kumar
Department of Statistics, Institute of Liver and Biliary Sciences, Delhi, India
,
Puja Sahai
Department of Radiation Oncology, Institute of Liver and Biliary Sciences, Delhi, India
,
Hanuman Prasad Yadav
Department of Radiation Oncology, Institute of Liver and Biliary Sciences, Delhi, India
› Author Affiliations Financial support and sponsorship Nil.
› Further Information
   Permissions and Reprints

Abstract

Background: Cancer accounts for about 1 in 7 deaths, worldwide. Primary cancers of the hepatobiliary system are significant health problems worldwide and their management presents great challenges for the hepatobiliary specialist. The incidence of hepatobiliary malignancies is on an increasing trend in India. Study: We did a retrospective study for the epidemiologic, clinical characteristics, and outcomes of patients with cancer registering for treatment in the oncology division at the Institute of Liver and Biliary Sciences, Delhi, India, between January 1, 2017 and December 31, 2017. Results: Atotal of 502 new patients were registered during the study period. The majority of the patients were male (M:F 1.69:1), in the age group of 35–64 years (64.3%) and presented in advanced stages of the disease (72.7% in Stage III and IV). The most common cancers were gallbladder cancer (GBC) (29.7%) and hepatocellular carcinoma (HCC) (17.3%). GBC was the most common in females (M: F 1:1.6), 86.6% were advanced (Stage III and IV), and gallstones were present in 44.3% patients (M: F 1:2.9). Periampullary carcinoma presented in early stages (71% in Stage I and II). Survival at 6 months (n = 110 evaluable patients) was 100% for Stage I, 88% for Stage II, 73.7% for Stage III and 42.1% for Stage IV, and 62.7% overall (P < 0.001). Survival at 6 months (n = 123 evaluable patients) was 56.5% for biliary cancers, 71.4% for HCC, and 75% for nonbiliary cancers (P = 0.15). 217 (43%) patients had one visit to the hospital and 168 (34%) patients had 2–5 visits with no or little follow-up. Conclusions: Most of the disease burden was in the male gender (GBC was more common in females), in the age group 35–64 years and with advanced disease presentation (except periampullary cancer). Survival diminished significantly with increasing stage of disease. Survival was worse for patients with biliary cancers. This could be due to advanced presentation, poor follow-up, and inadequate public health awareness.

Keywords

Epidemiology - gallbladder cancer - hepatobiliary cancers - hepatocellular cancer - periampullary carcinoma


Publication History

Received: 07 September 2018

Accepted: 10 November 2019

Article published online:
28 June 2021

© 2020. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Available from: https://www.cancer.org/research/cancer-facts- statistics/all-cancer-facts-figures/cancer-facts-figures-2017.html. [Last accessed on 2018 Apr 01].
  • 2 National Cancer Registry Programme. Hospital Based (2012-2014) and Population Based (2012-2014) Cancer Registry Reports. New Delhi, India: Indian Council of Medical Research; 18, May 2016
  • 3 Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M. et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer 2019; 144: 1941-53
    CrossrefPubMedGoogle Scholar
  • 4 Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108
    CrossrefPubMedGoogle Scholar
  • 5 Ahmed F, Perz JF, Kwong S, Jamison PM, Friedman C, Bell BP. National trends and disparities in the incidence of hepatocellular carcinoma, 1998-2003. Prev Chronic Dis 2008; 5: A74
    PubMedGoogle Scholar
  • 6 Llovet JM. Updated treatment approach to hepatocellular carcinoma. J Gastroenterol 2005; 40: 225 –235
    CrossrefPubMedGoogle Scholar
  • 7 Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30
    CrossrefPubMedGoogle Scholar
  • 8 Seitz HK, Stickel F. Risk factors and mechanisms of hepatocarcinogenesis with special emphasis on alcohol and oxidative stress. Biol Chem 2006; 387: 349-60
    CrossrefPubMedGoogle Scholar
  • 9 Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, Zein NN. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010; 51: 1972-8
    CrossrefPubMedGoogle Scholar
  • 10 Ertle J, Dechêne A, Sowa JP, Penndorf V, Herzer K, Kaiser G. et al. Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int J Cancer 2011; 128: 2436-43
    CrossrefPubMedGoogle Scholar
  • 11 Starley BQ, Calcagno CJ, Harrison SA. et al. Nonalcoholic fatty liver disease and hepatocellular carcinoma: A weighty connection. Hepatology 2010; 51: 1820-32
    CrossrefPubMedGoogle Scholar
  • 12 Guzman G, Brunt EM, Petrovic LM, Chejfec G, Layden TJ, Cotler SJ. Does nonalcoholic fatty liver disease predispose patients to hepatocellular carcinoma in the absence of cirrhosis?. Arch Pathol Lab Med 2008; 132: 1761-6
    CrossrefPubMedGoogle Scholar
  • 13 Wistuba II, Gazdar AF. Gallbladder cancer: Lessons from a rare tumour. Nat Rev Cancer 2004; 4: 695-706
    CrossrefPubMedGoogle Scholar
  • 14 Hundal R, Shaffer EA. Gallbladder cancer: Epidemiology and outcome. Clin Epidemiol 2014; 6: 99-109
    Google Scholar
  • 15 Randi G, Franceschi S, La Vecchia C. Gallbladder cancer worldwide: Geographical distribution and risk factors. Int J Cancer 2006; 118: 1591-602
    CrossrefPubMedGoogle Scholar
  • 16 Lazcano-Ponce EC, Miquel JF, Muñoz N, Herrero R, Ferrecio C, Wistuba II. et al. Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin 2001; 51: 349-64
    CrossrefPubMedGoogle Scholar
  • 17 Nervi F, Duarte I, Gómez G, Rodríguez G, Del Pino G, Ferrerio O. et al. Frequency of gallbladder cancer in Chile, a high-risk area. Int J Cancer 1988; 41: 657-60
    CrossrefPubMedGoogle Scholar
  • 18 Dhir V, Mohandas KM. Epidemiology of digestive tract cancers in India IV. Gall bladder and pancreas. Indian J Gastroenterol 1999; 18: 24-8
    PubMedGoogle Scholar
  • 19 Pilgrim CH, Groeschl RT, Christians KK, Gamblin TC. Modern perspectives on factors predisposing to the development of gallbladder cancer. HPB (Oxford) 2013; 15: 839-44
    CrossrefPubMedGoogle Scholar
  • 20 Iyer P, Barreto SG, Sahoo B, Chandrani P, Ramadwar MR, Shrikhande SV. et al. Non-typhoidal Salmonella DNA traces in gallbladder cancer. Infect Agent Cancer 2016; 11: 12
    CrossrefPubMedGoogle Scholar
  • 21 De Aretxabala X, Roa I, Araya JC, Burgos L, Flores P, Wistuba I. et al. Gallbladder cancer in patients less than 40 years old. Br J Surg 1994; 81: 111
    CrossrefPubMedGoogle Scholar
  • 22 Saika K, Matsuda T. Comparison of time trends in gallbladder cancer mortality (1990-2006) between countries based using the WHO mortality database. Jpn J Clin Oncol 2010; 40: 374-5
    CrossrefPubMedGoogle Scholar
  • 23 Sinha S, Piehler JM, Crichlow RW. Primary carcinoma of the gallbladder. Surg Gynecol Obstet 1978; 147: 929-42
    PubMedGoogle Scholar
  • 24 Diehl AK, Beral V. Cholecystectomy and changing mortality from gallbladder cancer. Lancet 1981; 2: 187-9
    CrossrefPubMedGoogle Scholar
  • 25 Mohandas KM, Patil PS. Cholecystectomy for asymptomatic gallstones can reduce gall bladder cancer mortality in Northern Indian women. Indian J Gastroenterol 2006; 25: 147-51
    PubMedGoogle Scholar
  • 26 Kamisawa T, Tu Y, Kuwata G, Egawa N, Nakajima H, Tsuruta K. Biliary carcinoma risk in patients with pancreaticobiliary maljunction and the degree of extrahepatic bile duct dilatation. Hepatogastroenterology 2006; 53: 816-8
    PubMedGoogle Scholar
  • 27 Stephen AE, Berger DL. Carcinoma in the porcelain gallbladder: A relationship revisited. Surgery 2001; 129: 699-703
    CrossrefPubMedGoogle Scholar
  • 28 Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 2001; 33: 1353-7
    CrossrefPubMedGoogle Scholar
  • 29 Patel T. Worldwide trends in mortality from biliary tract malignancies. BMC Cancer 2002; 2: 10
    CrossrefPubMedGoogle Scholar
  • 30 Riall TS, Nealon WH, Goodwin JS, Zhang D, Kuo YF, Townsend CMJr. et al. Pancreatic cancer in the general population: Improvements in survival over the last decade. J Gastrointest Surg 2006; 10: 1212-23
    CrossrefPubMedGoogle Scholar
  • 31 Solomon S, Das S, Brand R, Whitcomb DC. Inherited pancreatic cancer syndromes. Cancer J 2012; 18: 485-91
    CrossrefPubMedGoogle Scholar
  • 32 Iodice S, Gandini S, Maisonneuve P, Lowenfels AB. Tobacco and the risk of pancreatic cancer: A review and meta-analysis. Langenbecks Arch Surg 2008; 393: 535-45
    CrossrefPubMedGoogle Scholar
  • 33 Andreotti G, Silverman DT. Occupational risk factors and pancreatic cancer: A review of recent findings. Mol Carcinog 2012; 51: 98-108
    CrossrefPubMedGoogle Scholar
  • 34 Lucenteforte E, La Vecchia C, Silverman D, Petersen GM, Bracci PM, Ji BT. et al. Alcohol consumption and pancreatic cancer: A pooled analysis in the International Pancreatic Cancer Case-Control Consortium (PanC4). Ann Oncol 2012; 23: 374-82
    CrossrefPubMedGoogle Scholar
  • 35 Duell EJ, Lucenteforte E, Olson SH, Bracci PM, Li D, Risch HA. et al. Pancreatitis and pancreatic cancer risk: A pooled analysis in the International Pancreatic Cancer Case-Control Consortium (PanC4). Ann Oncol 2012; 23: 2964-70
    CrossrefPubMedGoogle Scholar
  • 36 Huxley R, Ansary-Moghaddam A, Berrington de GonzálezA, Barzi F, Woodward M. Type-II diabetes and pancreatic cancer: A meta-analysis of 36 studies. Br J Cancer 2005; 92: 2076-83
    CrossrefPubMedGoogle Scholar
  • 37 Ben Q, Xu M, Ning X, Liu J, Hong S, Huang W. et al. Diabetes mellitus and risk of pancreatic cancer: A meta-analysis of cohort studies. Eur J Cancer 2011; 47: 1928-37
    CrossrefPubMedGoogle Scholar
  • 38 Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE. et al. One hundred years after “carcinoid”: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008; 26: 3063-72
    CrossrefPubMedGoogle Scholar
  • 39 Lam KY, Lo CY. Pancreatic endocrine tumour: A 22-year clinico-pathological experience with morphological, immunohistochemical observation and a review of the literature. Eur J Surg Oncol 1997; 23: 36-42
    CrossrefPubMedGoogle Scholar
  • 40 Yao JC, Eisner MP, Leary C, Dagohoy C, Phan A, Rashid A. et al. Population-based study of islet cell carcinoma. Ann Surg Oncol 2007; 14: 3492-500
    CrossrefPubMedGoogle Scholar
  • 41 de HerderWW, Kwekkeboom DJ, Feelders RA, van AkenMO, Lamberts SW, van der LelyAJ. et al. Somatostatin receptor imaging for neuroendocrine tumors. Pituitary 2006; 9: 243-8
    CrossrefPubMedGoogle Scholar
  • 42 Mocellin S, Nitti D. Gastrointestinal carcinoid: Epidemiological and survival evidence from a large population-based study (n=25 531). Ann Oncol 2013; 24: 3040-4
    CrossrefPubMedGoogle Scholar
  • 43 Patel T, Sarin YK. Cholangiocarcinoma–controversies and challenges. Nat Rev Gastroenterol Hepatol 2011; 8: 189-200
    CrossrefPubMedGoogle Scholar
  • 44 Shukla HS, Sirohi B, Behari A, Sharma A, Majumdar J, Ganguly M. et al. Indian Council of Medical Research. consensus document for the management of gall bladder cancer. Indian J Med Paediatr Oncol 2015; 36: 79-84
    Article in Thieme ConnectPubMedGoogle Scholar
  • 45 DeOliveira ML, Cunningham SC, Cameron JL, Kamangar F, Winter JM, Lillemoe KD. et al. Cholangiocarcinoma: Thirty-one-year experience with 564 patients at a single institution. Ann Surg 2007; 245: 755-62
    CrossrefPubMedGoogle Scholar
  • 46 Hemming AW, Reed AI, Fujita S, Foley DP, Howard RJ. Surgical management of hilar cholangiocarcinoma. Ann Surg 2005; 241: 693-9
    CrossrefPubMedGoogle Scholar
  • 47 Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A. et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010; 362: 1273-81
    CrossrefPubMedGoogle Scholar